Durability of Vaccine Responses
NCT05801978 is a phase 4 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is recruiting participants. It studies Live Attenuated Yellow Fever 17D Vaccine and Quadrivalent seasonal influenza vaccine in Vaccine Response. The registry lists an enrollment of 66 participants at 3 sites in 1 country. The registry lists a start date of 11 Apr 2023 and a primary completion date of 30 Sept 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05801978 |
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Emory University |
| Enrollment | 66 |
| Registered sites | 3 |
| Countries | 1 |
| Conditions | Vaccine Response |
| Drugs | Live Attenuated Yellow Fever 17D Vaccine and Quadrivalent seasonal influenza vaccine |
| Start | 11 Apr 2023 |
| Primary completion | 30 Sept 2027 |
| Study completion | 30 Sept 2027 |
| Last update posted | 17 Jul 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory University Hospital
Atlanta
Recruiting - Emory Winship Cancer Institute
Atlanta
Recruiting - the Hope Clinic of Emory University
Decatur
Recruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05801978
Each answer restates registry values shown on this page.
What is NCT05801978?
NCT05801978 is a phase 4 interventional trial sponsored by Emory University. It studies Live Attenuated Yellow Fever 17D Vaccine and Quadrivalent seasonal influenza vaccine in Vaccine Response.
Is NCT05801978 recruiting?
As of 21 Nov 2026, it is recruiting participants. 3 of its 3 sites list their own status as recruiting.
Who leads NCT05801978?
The registry names Nadine Rouphael, MD (principal investigator, Emory University) as the overall official.
Where does NCT05801978 run?
The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05801978 study?
The registered drug and biological interventions are Live Attenuated Yellow Fever 17D Vaccine and Quadrivalent seasonal influenza vaccine.
When is NCT05801978 expected to complete?
The registry lists a primary completion date of 30 Sept 2027 and a study completion date of 30 Sept 2027. The sponsor last updated the record on 17 Jul 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.